Pfizer already reported its experimental drug for hemophilia A and B met a pivotal study’s goals of reducing bleeding episodes. During the annual meeting of the American Society of Hematology, the company presented a full look at the results, which are expected to support regulatory submissions soon.
Russell P. Gollard, MD, FACP, explores effective collaboration among health care professionals, administrators, and specialty pharmacies in managing rare diseases like hemophilia A.
Atta Chowdhry, RPh, and Robert Sidonio Jr, MD, MSc, discuss the safety and efficacy of gene therapy for hemophilia A, highlighting recent approvals, with insights into adverse effects, immunosuppression, and the evolving treatment landscape.
Experts discuss adherence to emicizumab in real-world settings, comparing it to factor products and highlighting the convenience and ease of administration associated with emicizumab.
Russell P. Gollard, MD, FACP, discusses how the rising costs of managing hemophilia A are influenced by drug expenses, treatment efficacy, and adverse events, creating significant financial burdens across health care settings and patient populations.